P3 Health Partners Inc.
No enriched coverage for $PIII in the last 7 days.
P3 Health Partners (PIII) reported Q2 2026 adjusted EBITDA of $54.4 million versus a prior-year loss, on total revenue of $386.4 million (+9% YoY). At-risk membership fell 10% to 105,000. Net income was $15.7 million. The company raised full-year 2026 guidance to adjusted EBITDA of $80 million to $110 million and revenue of $1.5 billion to $1.6 billion.
Hudson Vegas Investment SPV, LLC sold 50,000 shares of P3 Health Partners Inc. (PIII) at an average of $16.48 ($13.38–$16.86, $0.82M total) across 3 trades on 2026-08-10.
P3 Health Partners (PIII) reported Q2 2026 revenue of $386.4 million, up 9% from $355.8 million a year earlier, and swung to net income of $15.7 million versus a $43.7 million loss. Adjusted EBITDA was $54.4 million. The company raised FY2026 guidance to $80-$110 million adjusted EBITDA and $1.5-$1.6 billion revenue.
Recent PIII coverage spans earnings, corporate actions and market movers.
In the last 30 days, PIII insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($824K). The most active reporter was Hudson Vegas Investment SPV, LLC with 3 filings.
Guidance raise plus improved underlying profitability suggests a lower-risk earnings profile, supporting a positive re-rating versus prior loss periods.
This is a disclosed insider sale by a large holder, with no 10b5-1 plan cited, which can modestly pressure sentiment but is not a fundamental update.
Guidance lift and swing to profitability are likely to support near-term sentiment and valuation, but execution risk remains given at-risk membership decline.
The 8-K discloses a profitability inflection in Q2 and a higher full-year adjusted EBITDA outlook, which can re-rate near-term expectations.
The 8-K discloses a balance-sheet/financing change: longer maturity plus higher PIK accrual, which can increase future debt burden and affect credit risk perception.
alphai scores every news story that mentions PIII with an AI model for sentiment and relevance, and aggregates insider trades from P3 Health Partners Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
P3 Health Partners (PIII) reported Q2 2026 adjusted EBITDA of $54.4 million versus a prior-year loss, on total revenue of $386.4 million (+9% YoY). At-risk membership fell 10% to 105,000. Net income was $15.7 million. The company raised full-year 2026 guidance to adjusted EBITDA of $80 million to $110 million and revenue of $1.5 billion to $1.6 billion.
7 min readHudson Vegas Investment SPV, LLC sold 50,000 shares of P3 Health Partners Inc. (PIII) at an average of $16.48 ($13.38–$16.86, $0.82M total) across 3 trades on 2026-08-10.
2 min readP3 Health Partners (PIII) reported Q2 2026 revenue of $386.4 million, up 9% from $355.8 million a year earlier, and swung to net income of $15.7 million versus a $43.7 million loss. Adjusted EBITDA was $54.4 million. The company raised FY2026 guidance to $80-$110 million adjusted EBITDA and $1.5-$1.6 billion revenue.
6 min readP3 Health Partners Inc. (PIII) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 P3 Health Partners Announces Second Quarter 2026 Results Raises Full-Year 2026 Adjusted EBITDA Guidance Management to Host Conference Call and Webcast August 10, 2026 at 4:30 PM ET HENDERSON, NV—August 10, 2026—P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ:
6 min readP3 Health Partners Inc. (PIII) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. piii-20260630 0001832511 false 0001832511 2026-06-30 2026-06-30 0001832511 us-gaap:CommonClassAMember 2026-06-30 2026-06-30 0001832511 us-gaap:WarrantMember 2026-06-30 2026-06-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSU
2 min readP3 Health Partners Inc. (PIII) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. piii-20260609 0001832511 false 0001832511 2026-06-09 2026-06-09 0001832511 us-gaap:CommonClassAMember 2026-06-09 2026-06-09 0001832511 us-gaap:WarrantMember 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSU
2 min readP3 Health Partners (NASDAQ:PIII) reported short interest of 283,541 shares as of May 15, up 293.3% from 72,094 on April 30; about 4.8% of shares are sold short, with a days-to-cover ratio near 0.0. The stock fell 26% on Friday to $12.18. UBS and Lake Street set $14 targets; TD Cowen reiterated hold. The company reported Q1 EPS of $0.32 on revenue of $386.39M.
4 min readBiotech stocks rose on varied catalysts. Q32 Bio (QTTB) jumped 85% after a $55M private placement at $8.00/share; topline SIGNAL-AA Phase 2a Part B data are expected mid-2026. Soligenix (SNGX) gained 69% as it evaluates ThermoVax for Bundibugyo Ebola. Guardant (GH) rose 6% after ACS added its Shield blood test to updated colorectal screening guidelines; Q1 revenue was $301.7M (+48%).
6 min readP3 Health Partners (PIII) has seen its price target reduced by 12.50% to $3.57. This adjustment reflects a change in analyst expectations for the company's future stock performance. Investors will likely monitor further developments and analyst reports regarding PIII.
3 min readImage source: The Motley Fool.Thursday, Aug. 14, 2025 at 4:30 p.m. ETChief Executive Officer - Aric CoffmanContinue reading ...
3 min read
